GENFIT Reveals Half-Year Overview of Liquidity Contract
GENFIT (NASDAQ: GNFT), a leading biopharmaceutical organization focused on developing innovative solutions for patients with serious liver diseases, recently shared significant insights into their liquidity contract with Crédit Industriel et Commercial. This report reflects the company’s commitment to transparency and detailed updates on their financial activities.
Liquidity Account Resources as of June 30
As of the end of June 2025, the liquidity account disclosed some promising figures:
- 201,100 shares in liquidity
- €398,484.67 in cash reserves
Trading Activities in 2025
Throughout the first half of 2025, GENFIT saw substantial trading volumes. Here’s a breakdown of these activities:
- Buying Activity: 1,412,901 shares bought for a total of €5,016,550.43
- Selling Activity: 1,419,301 shares sold, amounting to €5,061,074.96
Trade Volumes
The trading activity also encompassed various executions:
- Buy Executions: 2,673 total trades
- Sell Executions: 1,894 trades
Initial Contract Position
Upon commencement of this liquidity contract, the initial resources in the account were as follows:
- 27,911 shares
- €769,849.43 in cash holdings
About GENFIT
Founded two decades ago, GENFIT has steadfastly dedicated itself to the research and development of novel treatments for liver diseases. Their flagship focus is on Acute-on-Chronic Liver Failure (ACLF). With a robust research and development portfolio, the company is advancing several therapies, including:
- VS-01
- G1090N
- SRT-015
- CLM-022
- VS-02-HE
Moreover, GENFIT is pioneering diagnostics for conditions like metabolic dysfunction-associated steatohepatitis (MASH) with its NIS2+® diagnostic.
Investment and Stakeholder Relations
In recent years, GENFIT has attracted significant investments. Notably, Ipsen became one of the largest shareholders by acquiring an 8% stake in the company’s capital. This partnership demonstrates the confidence investors place in GENFIT's potential to revolutionize treatments for liver diseases.
Future Outlook
While the report reflects GENFIT's past and current activities, it also sets the stage for future endeavors. The ongoing commitment to innovative drug development and diagnostics aligns with the company’s vision to meet the unmet needs of patients suffering from liver disorders.
Frequently Asked Questions
What is GENFIT's primary focus?
GENFIT primarily concentrates on developing treatments and diagnostic solutions for serious liver diseases like ACLF and metabolic dysfunction-associated steatohepatitis.
How much liquidity does GENFIT have as of June 30, 2025?
As of June 30, 2025, GENFIT has €398,484.67 in cash reserves and 201,100 shares in its liquidity account.
What were the total trading figures for GENFIT in the first half of 2025?
In the first half of 2025, GENFIT had 1,412,901 shares bought and 1,419,301 shares sold, totaling approximately €10 million in combined trading.
Who are the key stakeholders in GENFIT?
One of the significant stakeholders in GENFIT is Ipsen, which holds an 8% stake in the company.
Where is GENFIT headquartered?
GENFIT is headquartered in Lille, France, with additional offices in Paris and Zurich.
